New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

February 6, 2024

https://www.globenewswire.com/news-release/2024/02/06/2824357/0/en/New-Publication-Identifies-Key-Proteins-Involved-in-Amyloid-Oligomer-Binding-and-Supports-Mechanism-of-CT1812.html

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, (doi: 10.1007/s00401-023-02679-6) that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding. 

Read more at globenewswire.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.